Boserolimab

Phase 2Monoclonal antibody

Merck & Co.

Boserolimab is one of 48 biologic programs targeting Carcinoma, Non-Small-Cell Lung. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Carcinoma, Non-Small-Cell LungCompleted

Carcinoma, Non-Small-Cell LungPhase 2

Completed

Competition

Competitive Landscape

53 competitors in Carcinoma, Non-Small-Cell Lung

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

14 2

Rybrevant

Johnson & Johnson

Phase 3

13 3

Lazcluze

Johnson & Johnson

Phase 3

8 4

Imfinzi

AstraZeneca

Phase 3

7 5

Taxol

Teva

Phase 3

4 6

Paraplatin

AAvyxa

Phase 3

16 7

Tagrisso

AstraZeneca

Phase 3

3 8

Alimta

EEagle Pharmaceuticals, Inc.

Phase 3

13 9

Alimta

SShawn Eagle

Phase 3

11 10

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2032

PreclinicalRecruiting

Carcinoma, Non-Small-Cell Lung

NCT04165070

Clinical

Trials by Indication[1]

Carcinoma, Non-Small-Cell Lung2 trials

KEYMAKER-U01 Substudy 01A: A Phase 1/2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab With or Without Chemotherapy in Treatment-Naive Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT04165070·450 enrolled

KEYMAKER-U01 Substudy 3: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Anti-PD-(L)1 Therapy

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT04165096·128 enrolled

Advanced Solid Tumors1 trial

Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT03396445·182 enrolled

Triple-Negative Breast Cancer1 trial

A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)

Withdrawn· Merck & Co. logo

Merck & Co.·Phase 2·NCT06829199

Small Cell Lung Cancer1 trial

A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT04924101·122 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Boserolimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Boserolimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Boserolimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: Merck & Co.

Boserolimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2032

Trials by Indication[1]

Carcinoma, Non-Small-Cell Lung2 trials

Advanced Solid Tumors1 trial

Triple-Negative Breast Cancer1 trial

Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News